{"questions": [{"id": "63f73f1b33942b094c000008", "type": "yesno", "body": "Is erenumab effective for trigeminal neuralgia?", "ideal": "Erenumab is a monoclonal antibody that has been studied for its potential to treat trigeminal neuralgia, a chronic pain condition that affects the trigeminal nerve. Studies have shown that erenumab can reduce the frequency and intensity of trigeminal neuralgia pain episodes, as well as improve quality of life for those with the condition. However, further research is needed to determine the long-term efficacy and safety of erenumab for treating trigeminal neuralgia.", "exacta": "No", "clave": "1. Erenumab\n2. Trigeminal Neuralgia\n3. Neuropathic Pain\n4. Facial Pain\n5. Neurovascular Compression\n6. Anti-CGRP Therapy\n7. Calcitonin Gene-Related Peptide\n8. Monoclonal Antibody\n9. Clinical Trials\n10. Migraine Prevention", "short": "Yes, erenumab has been found to be effective in treating trigeminal neuralgia. Studies have shown that it can reduce pain intensity and improve quality of life for those with the condition."}, {"id": "643d41e757b1c7a315000037", "type": "list", "body": "What is the first indication for lurasidone?", "ideal": "Lurasidone is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. It is the first medication to be approved by the FDA for the treatment of bipolar depression. It works by blocking the action of certain neurotransmitters in the brain, which helps to reduce symptoms of psychosis and depression. It is usually taken once daily, with or without food. Common side effects include nausea, headache, and insomnia.", "exacta": ["Major Depressive Disorder"], "clave": "Lurasidone, Schizophrenia, Antipsychotic, Major Depressive Disorder, Atypical Antipsychotic, Mania, Bipolar Disorder, Agitation, Psychosis, Neuroleptic, Serotonin Reuptake Inhibitor, Dopamine Receptor Antagonist, 5-HT2A Receptor Antagonist, 5-HT7 Receptor Antagonist.", "short": "Lurasidone is indicated for the treatment of schizophrenia in adults. It is also used to treat episodes of mania or mixed episodes in adults with bipolar I disorder."}, {"id": "643c88a257b1c7a315000030", "type": "yesno", "body": "Can other vaccines be given with COVID-19 vaccine?", "ideal": "Yes, other vaccines can be given with the COVID-19 vaccine. The Centers for Disease Control and Prevention (CDC) recommends that people get all recommended vaccines, including the COVID-19 vaccine, at the same time if possible. Vaccines should be given at least 4 weeks apart to ensure the best protection. It is important to talk to your healthcare provider about any other vaccines you may need and when to get them.", "exacta": "Yes", "clave": "1. Vaccine Interference \n2. Vaccine Scheduling \n3. Vaccine Sequencing \n4. Vaccine Compatibility \n5. Vaccine Co-administration \n6. Vaccine Interchangeability \n7. Vaccine Synergy \n8. Vaccine Interaction \n9. Vaccine Co-immunization \n10. Vaccine Co-inoculation", "short": "Yes, other vaccines can be given with the COVID-19 vaccine. It is safe to receive other vaccines at the same time or at any interval before or after the COVID-19 vaccine."}, {"id": "64403c4257b1c7a31500004f", "type": "summary", "body": "What is Sublocade?", "ideal": "Sublocade is a prescription medication used to treat opioid use disorder. It is an extended-release injectable form of buprenorphine, a medication used to reduce cravings and withdrawal symptoms associated with opioid addiction. Sublocade is administered once a month by a healthcare provider and is intended to be used in combination with counseling and other support services.", "exacta": "", "clave": "1. Buprenorphine\n2. Naltrexone\n3. Opioid Agonist\n4. Opioid Antagonist\n5. Extended-Release Injectable\n6. Monthly Injectable\n7. Medication-Assisted Treatment\n8. Opioid Dependence\n9. Opioid Use Disorder\n10. Opioid Withdrawal", "short": "Sublocade is a prescription medication used to treat opioid use disorder. It is a monthly injection of buprenorphine, a medication that helps reduce cravings and withdrawal symptoms."}, {"id": "6441302d57b1c7a315000056", "type": "yesno", "body": "Is music therapy effective for pain management in neonates?", "ideal": "Music therapy has been found to be an effective tool for pain management in neonates. Studies have shown that music therapy can reduce pain levels in neonates, as well as reduce the need for medication. Music therapy can also help to reduce stress and anxiety in neonates, as well as improve their overall well-being. Music therapy has been found to be a safe and non-invasive way to manage pain in neonates.", "exacta": "Yes", "clave": "Neonates, Music Therapy, Pain Management, Analgesia, Infants, Neonatal Intensive Care Unit (NICU), Non-pharmacological Interventions, Neurodevelopmental Outcomes, Stress Reduction, Autonomic Nervous System Regulation.", "short": "Yes, music therapy has been found to be effective for pain management in neonates. Studies have shown that music therapy can reduce pain levels and improve physiological responses to painful procedures."}, {"id": "63f042e2f36125a426000022", "type": "summary", "body": "What is the mechanisms of action of Gilteritinib?", "ideal": "Gilteritinib is an oral medication used to treat adults with relapsed or refractory acute myeloid leukemia (AML). It works by inhibiting the activity of a protein called FLT3, which is found in high levels in many AML cells. By blocking FLT3, Gilteritinib helps to reduce the growth and spread of cancer cells. It also helps to reduce the number of immature white blood cells in the bone marrow, which can help to reduce the risk of infection.", "exacta": "", "clave": "1. Tyrosine Kinase Inhibitor\n2. Receptor Tyrosine Kinase\n3. FLT3\n4. FLT3-ITD\n5. FLT3-TKD\n6. FLT3-D835Y\n7. FLT3-Activating Mutations\n8. FLT3-Internal Tandem Duplication\n9. FLT3-Tyrosine Kinase Domain Mutations\n10. Gilteritinib", "short": "Gilteritinib is an oral tyrosine kinase inhibitor that works by blocking the activity of certain enzymes that are involved in the growth and spread of cancer cells."}, {"id": "64184483690f196b51000038", "type": "summary", "body": "What is the reason for N-acetylgalactosamine (GalNAc) conjugation of siRNAs?", "ideal": "N-acetylgalactosamine (GalNAc) conjugation of siRNAs is a process used to improve the stability and delivery of siRNAs to target cells. This process involves attaching a GalNAc molecule to the siRNA, which helps protect the siRNA from degradation and increases its ability to enter the cell. Additionally, the GalNAc molecule can be used to target the siRNA to specific cell types, allowing for more precise delivery of the siRNA.", "exacta": "", "clave": "1. N-Acetylgalactosamine (GalNAc) \n2. siRNA \n3. Conjugation \n4. Post-transcriptional Modification \n5. O-GlcNAcylation \n6. Glycosylation \n7. Enzymatic Activity \n8. Protein Kinase \n9. Nucleic Acid Delivery \n10. Targeted Delivery", "short": "GalNAc conjugation of siRNAs helps to increase their stability and target delivery, allowing them to be more effective in silencing gene expression."}, {"id": "643de76757b1c7a315000039", "type": "summary", "body": "What is synthetic lethality?", "ideal": "Synthetic lethality is a phenomenon in which two or more genetic mutations interact in a way that causes a cell to die, even though each mutation alone would not be lethal. This phenomenon is used in cancer research to identify potential drug targets, as it can be used to selectively target cancer cells while leaving healthy cells unharmed.", "exacta": "", "clave": "Synthetic lethality: \n\n-Genetic Interaction\n-Epistasis\n-RNA Interference\n-CRISPR-Cas9\n-Gene Knockout\n-Gene Silencing\n-Gene Editing\n-Gene Expression\n-Post-Transcriptional Regulation\n-Protein Interaction\n-Phenotypic Screening", "short": "Synthetic lethality is a phenomenon in which two or more genetic mutations interact to cause cell death, even though each mutation alone would not be lethal."}, {"id": "64403ab057b1c7a31500004d", "type": "factoid", "body": "How many injections of CLS-TA did the patients participating in the PEACHTREE trial receive?", "ideal": "The PEACHTREE trial was a Phase 3 clinical trial that evaluated the safety and efficacy of CLS-TA, a novel therapeutic agent for the treatment of moderate-to-severe plaque psoriasis. Patients in the trial received either a single injection of CLS-TA or a placebo. The patients who received CLS-TA received three injections of the drug at weeks 0, 4, and 8.", "exacta": ["PEACHTREE trial", "injections", "CLS-TA", "patients", "confidence"], "clave": ".\n\nInjections, CLS-TA, PEACHTREE, Clinical Trial, Dosage, Administration, Treatment, Outcome, Safety, Efficacy.", "short": "The PEACHTREE trial participants received a total of three injections of CLS-TA, one at baseline and two at weeks 4 and 8."}, {"id": "64179139690f196b5100002f", "type": "list", "body": "What are the most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy?", "ideal": "The most commonly used diagnostic tests for the diagnosis of Duchenne muscular dystrophy are genetic testing, muscle biopsy, and electromyography (EMG). Genetic testing is used to identify mutations in the dystrophin gene, which is responsible for the disease. Muscle biopsy is used to examine the muscle tissue for signs of damage. EMG is used to measure the electrical activity of the muscles and can help to identify muscle weakness.", "exacta": ["Creatine Kinase Test", "DNA Testing", "Muscle Biopsy", "Electromyography"], "clave": "1. Creatine Kinase (CK)\n2. Dystrophin\n3. Electromyography (EMG)\n4. Genetic Testing\n5. Muscle Biopsy\n6. Serum Enzyme Analysis\n7. Serum Creatine Kinase (CK)\n8. Serum Lactate Dehydrogenase (LDH)\n9. X-ray Imaging", "short": "The most commonly used diagnostic tests for Duchenne muscular dystrophy are genetic testing, muscle biopsy, and creatine kinase (CK) testing."}, {"id": "63f02b50f36125a426000014", "type": "yesno", "body": "Is there any association between Tripe palms and cancer?", "ideal": "Tripe palms is a rare skin condition that is characterized by the presence of multiple, small, red-brown spots on the palms of the hands. While there is no known cause for Tripe palms, some studies have suggested that there may be an association between Tripe palms and certain types of cancer, such as melanoma and non-melanoma skin cancer. However, further research is needed to confirm this potential link.", "exacta": "No", "clave": "1. Tripeptidyl Peptidase 1 (TPP1)\n2. Carcinogenesis\n3. Oncogenic Transformation\n4. Tumor Suppressor Genes\n5. Apoptosis\n6. Cell Cycle Regulation\n7. DNA Methylation\n8. Epigenetics\n9. Angiogenesis\n10. Metastasis", "short": "No, there is no scientific evidence to suggest that tripe palms are associated with cancer."}, {"id": "6411b678201352f04a000036", "type": "factoid", "body": "is prosopagnosia inherited or  acquired?", "ideal": "Prosopagnosia, also known as face blindness, is a neurological disorder that affects an individual's ability to recognize faces. It is not clear whether prosopagnosia is inherited or acquired, but research suggests that it is likely a combination of both. Studies have found that some people are born with a predisposition to the disorder, while others may develop it due to a traumatic brain injury or other neurological condition.", "exacta":["Inherited", "Acquired", "Genetic", "Hereditary", "Congenital"], "clave": "Inherited:\n-Genetic\n-Hereditary\n-Congenital\n\nAcquired:\n-Neurological\n-Traumatic\n-Developmental", "short": "Prosopagnosia is an acquired condition, meaning it is not inherited. It is a neurological disorder that impairs the ability to recognize faces."}, {"id": "643bc8f957b1c7a31500002b", "type": "factoid", "body": "Where are promoters typically found in DNA?", "ideal": "Promoters are DNA sequences that are found near the beginning of a gene and are responsible for controlling the expression of that gene. They are typically located upstream of the gene, and can be found in both prokaryotic and eukaryotic cells. Promoters are recognized by transcription factors, which bind to the promoter and initiate the transcription of the gene.", "exacta": ["Promoter", "Transcription Start Site", "Transcription Factor Binding Site", "Core Promoter", "Enhancer"], "clave": "Promoter, Transcription Factor, Regulatory Element, Transcription Start Site, Core Promoter, TATA Box, Cis-Regulatory Element, Enhancer, Repressor, Silencer.", "short": "Promoters are typically found upstream of the gene they regulate, usually within 100-1000 base pairs of the transcription start site."}, {"id": "64403be357b1c7a31500004e", "type": "factoid", "body": "What was the duration of the follow-up period of patients in the PEACHTREE clinical trial?", "ideal": "The PEACHTREE clinical trial was a Phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of a new drug for the treatment of chronic obstructive pulmonary disease (COPD). The study included a total of 1,902 patients who were randomized to receive either the new drug or placebo. The follow-up period for the trial was 24 weeks, with patients being monitored for safety and efficacy outcomes throughout the duration of the study.", "exacta": ["PEACHTREE Clinical Trial", "Follow-up Period", "Duration", "Patients", "Clinical Trials"], "clave": "1. Follow-up period\n2. PEACHTREE clinical trial\n3. Duration\n4. Longitudinal study\n5. Retrospective analysis\n6. Prospective cohort\n7. Outcome assessment\n8. Time-to-event analysis\n9. Survival analysis\n10. Adverse event monitoring", "short": "The PEACHTREE clinical trial had a follow-up period of 24 months, during which patients were monitored for changes in their symptoms and quality of life."}, {"id": "644289c457b1c7a31500005e", "type": "list", "body": "Which are some symptoms of FSHD?", "ideal": "FSHD (facioscapulohumeral muscular dystrophy) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. Common symptoms of FSHD include muscle weakness, muscle wasting, and difficulty with certain movements such as raising the arms above the head. Other symptoms may include scapular winging, foot drop, and facial weakness. In some cases, people with FSHD may experience difficulty with balance and coordination.", "exacta": ["Muscle Weakness", "Facial Droop", "Difficulty Chewing/Swallowing", "Scapular Winging", "Foot Drop", "Head Drop", "Difficulty Climbing Stairs"], "clave": "1. Facioscapulohumeral muscular dystrophy (FSHD)\n2. Proximal muscle weakness\n3. Scapular winging\n4. Facial muscle weakness\n5. Asymmetric muscle wasting\n6. Ptosis\n7. Ophthalmoplegia\n8. High-arched palate\n9. Abnormal gait\n10. Contractures", "short": "Common symptoms of FSHD include muscle weakness, pain, and wasting in the face, shoulders, and upper arms. Other symptoms may include scoliosis, difficulty speaking, and difficulty swallowing."}, {"id": "63f02ec1f36125a426000017", "type": "summary", "body": "What is the mechanism of action of Adagrasib?", "ideal": "Adagrasib is a small molecule inhibitor of the protein target, PCSK9. It works by binding to PCSK9 and blocking its activity, which in turn reduces the amount of LDL cholesterol in the blood. This mechanism of action helps to reduce the risk of cardiovascular disease.", "exacta": "", "clave": "1. Adagrasib \n2. Small molecule \n3. Selective androgen receptor modulator (SARM) \n4. Ligand-dependent transcriptional activation \n5. Nuclear receptor \n6. Receptor agonist \n7. Enzymatic activity \n8. Protein kinase \n9. Phosphorylation \n10. Signal transduction", "short": "Adagrasib works by blocking the activity of a protein called PCSK9, which helps regulate the amount of cholesterol in the blood. This reduces the amount of cholesterol in the body, helping to lower cholesterol levels and reduce the risk of"}, {"id": "641c516d690f196b5100003f", "type": "yesno", "body": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?", "ideal": "Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. Recent research has suggested that a mutation of the Super Oxide Dismutase 1 (SOD1) gene may be associated with ALS. Mutations of the SOD1 gene have been found in some cases of familial ALS, suggesting that the gene may play a role in the development of the disease. Further research is needed to determine the exact role of the SOD1 gene in ALS.", "exacta": "Yes", "clave": "Answer: Amyotrophic Lateral Sclerosis (ALS), Super Oxide Dismutase 1 (SOD1) gene, mutation, genetic mutation, familial ALS, SOD1 mutation, ALS-causing mutation, SOD1-linked ALS.", "short": "Yes, ALS can be associated with a mutation of the SOD1 gene. Mutations of this gene are responsible for up to 20% of familial ALS cases."}, {"id": "64371c5957b1c7a31500002a", "type": "summary", "body": "What are enhancers?", "ideal": "Enhancers are DNA sequences that can increase the expression of a gene. They are located upstream of the gene and can be located in the same or different chromosome. Enhancers can interact with transcription factors to increase the rate of transcription of the gene. Enhancers can also be regulated by epigenetic modifications, such as DNA methylation, histone modifications, and chromatin remodeling.", "exacta": "", "clave": "Enhancers are DNA sequences that regulate gene expression by increasing the rate of transcription. Related biomedical terms include: transcription factor, cis-regulatory element, enhancer element, enhancer binding protein, chromatin remodeling, epigenetic modification, and chromatin looping.", "short": "Enhancers are DNA sequences that increase the rate of transcription of a gene. They are located upstream of the gene and can be bound by transcription factors to increase the rate of transcription."}, {"id": "6440396957b1c7a31500004b", "type": "factoid", "body": "What is the mode of delivery of the drug XIPERE?", "ideal": "XIPERE is a drug that is delivered intravenously (IV) through a vein in the arm. It is administered as an infusion, meaning that it is slowly injected over a period of time. The drug is used to treat certain types of cancer, and is given in combination with other medications.", "exacta": ["Oral", "Tablet", "Capsule", "Liquid", "Injection"], "clave": "Answer: Oral, Intravenous, Subcutaneous, Intramuscular, Topical, Inhalation, Transdermal, Buccal, Rectal, Nasal, Ophthalmic.", "short": "The mode of delivery for XIPERE is intravenous infusion. It is administered directly into the bloodstream through a vein in the arm or hand."}, {"id": "641791ca690f196b51000031", "type": "list", "body": "What are the most common muscular dystrophies?", "ideal": "Muscular dystrophies are a group of inherited genetic disorders that cause progressive muscle weakness and wasting. The most common types of muscular dystrophies are Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy (DM), and congenital muscular dystrophy (CMD). These conditions can affect people of all ages, but are most commonly diagnosed in childhood. Symptoms vary depending on the type of muscular dystrophy, but can include muscle weakness, muscle wasting, difficulty walking, and difficulty with everyday activities.", "exacta": ["Duchenne Muscular Dystrophy", "Becker Muscular Dystrophy", "Limb-Girdle Muscular Dystrophy", "Facioscapulohumeral Muscular Dystrophy"], "clave": "Myotonic dystrophy, Duchenne muscular dystrophy, Becker muscular dystrophy, Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, Congenital muscular dystrophy, Oculopharyngeal muscular dystrophy, Distal muscular dystrophy, Emery-Dreifuss muscular dystrophy.", "short": "The most common muscular dystrophies are Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, and myot"}, {"id": "63eef7eff36125a42600000e", "type": "summary", "body": "Which disease is targeted by Fazirsiran?", "ideal": "Fazirsiran is a novel investigational RNA interference (RNAi) therapeutic being developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). PH1 is a rare, inherited metabolic disorder that can lead to the accumulation of oxalate in the body, resulting in kidney damage, kidney stones, and other serious complications. Fazirsiran is designed to reduce the production of the enzyme alanine-glyoxylate aminotransferase (AGT), which is responsible for the production of oxalate in PH1 patients. If approved, Fazirsiran would be the first RNAi therapeutic available for the treatment of PH1.", "exacta": "", "clave": "Fazirsiran: Transthyretin-Mediated Amyloidosis (ATTR-CM), Familial Amyloid Polyneuropathy (FAP), Cardiac Amyloidosis, Neuropathy, Autonomic Dysfunction, Protein Misfolding, TTR Gene Mutations, TTR Protein Aggregation, TTR Protein Deposition, TTR Protein Fibrils, TTR Protein Precipitation, TTR Protein Stabilization, TTR Protein Unfolding, TTR Protein Variants, TTR Protein Aggregates, TTR Protein Aggregation Inhibitors, TTR Protein Modulators, TTR Protein Structure, TTR Protein Targeting, TTR Protein Trafficking.", "short": "Fazirsiran is a drug being developed to treat primary hyperoxaluria, a rare genetic disorder that causes the body to produce too much oxalate, leading to kidney damage."}, {"id": "6431708a57b1c7a315000017", "type": "factoid", "body": "Where does Brain (or B type) Natriuretic Protein, BNP usually originate from?", "ideal": "Brain (or B type) Natriuretic Protein, BNP, is a hormone produced by the heart in response to increased pressure in the heart chambers. It is released into the bloodstream and can be measured to assess the amount of strain on the heart. BNP is used to diagnose and monitor heart failure, and can also be used to differentiate between heart failure and other conditions that cause similar symptoms.", "exacta": ["Cardiac Myocytes", "Atrial Myocytes", "Ventricular Myocytes", "Ventricular Endocardium", "Atrial Endocardium"], "clave": "Answer:\n\nMyocardium, Atrium, Ventricle, Cardiac Muscle, Cardiomyocytes, Endocardium, BNP Receptor, N-Terminal Pro-BNP, C-Terminal Pro-BNP, BNP Cleavage Enzyme.", "short": "Brain Natriuretic Protein (BNP) is a hormone produced by the heart. It is released in response to increased pressure in the heart, and helps to regulate blood pressure and fluid balance in the body."}, {"id": "643c396457b1c7a31500002d", "type": "yesno", "body": "Are any medications available to prevent COVID-19 following exposure?", "ideal": "At this time, there are no medications available to prevent COVID-19 following exposure. However, there are treatments available to help manage symptoms and reduce the severity of the illness. It is important to practice social distancing, wear a face covering, and follow other safety guidelines to reduce the risk of exposure.", "exacta": "No", "clave": ".\n\n1. SARS-CoV-2\n2. Post-Exposure Prophylaxis (PEP)\n3. Vaccines\n4. Antiviral Drugs\n5. Immunoglobulins\n6. Convalescent Plasma\n7. Monoclonal Antibodies", "short": "No, there are currently no medications available to prevent COVID-19 following exposure."}, {"id": "6440092d57b1c7a315000040", "type": "yesno", "body": "Has RTA 408 received FDA approval?", "ideal": "The FDA has not yet approved RTA 408, a drug developed by Regeneron Pharmaceuticals, Inc. for the treatment of certain types of cancer. Clinical trials are ongoing and the drug is currently in Phase 3 of the FDA approval process.", "exacta": "No", "clave": "FDA, Regulatory Approval, Drug Development, Clinical Trials, Investigational New Drug Application, Biologics License Application, Medical Device Approval, Pre-Market Approval, Post-Market Surveillance.", "short": "No, RTA 408 has not received FDA approval. It is an investigational drug being studied in clinical trials for the treatment of certain types of cancer."}, {"id": "644291fa57b1c7a31500005f", "type": "list", "body": "Which are the types of myotonic dystrophy?", "ideal": "Myotonic dystrophy is a genetic disorder that affects the muscles and other body systems. It is divided into two main types: myotonic dystrophy type 1 (DM1) and myotonic dystrophy type 2 (DM2). DM1 is the most common form and is characterized by muscle weakness, myotonia (muscle stiffness), and other symptoms such as cataracts, heart problems, and endocrine issues. DM2 is less common and is characterized by muscle weakness, myotonia, and other symptoms such as hearing loss, cognitive impairment, and respiratory problems.", "exacta": ["Myotonic Dystrophy Type 1", "Myotonic Dystrophy Type 2"], "clave": "Myotonic dystrophy type 1 (DM1), Myotonic dystrophy type 2 (DM2), Congenital myotonic dystrophy (CDM), Myotonic dystrophy-associated cardiac conduction defect (MDC), Facioscapulohumeral muscular dystrophy (FSHD), Oculopharyngeal muscular dystrophy (OPMD), Distal myotonic myopathy (DMM), and Proximal myotonic myopathy (PROMM).", "short": "There are two types of myotonic dystrophy: type 1 (DM1) and type 2 (DM2). DM1 is the most common form and is characterized by muscle weakness, myotonia, and other symptoms. DM"}, {"id": "63f741a633942b094c000009", "type": "list", "body": "What are the active components of Opdualag?", "ideal": "Opdualag is a combination of two active components: an opioid agonist and an opioid antagonist. The opioid agonist is a drug that binds to opioid receptors in the brain and produces a feeling of euphoria. The opioid antagonist is a drug that blocks the effects of the opioid agonist, preventing the user from feeling the effects of the opioid. Together, these two components work to reduce the risk of opioid overdose and addiction.", "exacta": ["Opioid", "Acetaminophen"], "clave": "1. Opioid Receptor Agonists \n2. Mu-Opioid Receptor \n3. Kappa-Opioid Receptor \n4. Delta-Opioid Receptor \n5. Endogenous Opioids \n6. Endorphins \n7. Enkephalins \n8. Dynorphins \n9. Nociceptin \n10. Nocistatin", "short": "Opdualag is a software platform that uses AI and machine learning to automate and optimize business processes. It consists of four main components: a workflow engine, a data analytics engine, an AI engine, and an API layer."}, {"id": "640f8641201352f04a00002c", "type": "factoid", "body": "Where in the body would  Schlemm's canal be found", "ideal": "?\n\nSchlemm's canal is a circular channel located in the eye, specifically in the trabecular meshwork of the anterior chamber angle. It is responsible for draining aqueous humor from the eye, allowing for the regulation of intraocular pressure.", "exacta": "?\n\nAnswer: Schlemm's Canal, Eye, Sclera, Cornea, Trabecular Meshwork", "clave": "1. Trabecular meshwork\n2. Schlemm's canal\n3. Aqueous humor\n4. Anterior chamber\n5. Canal of Schlemm\n6. Scleral venous sinus\n7. Scleral spur\n8. Ciliary body\n9. Intraocular pressure\n10. Ocular hypertension", "short": "Schlemm's canal is found in the eye. It is a circular channel located in the eye's outer wall that collects and drains aqueous humor from the anterior chamber of the eye."}, {"id": "643c446357b1c7a31500002f", "type": "yesno", "body": "Can reinfection occur after SARS-CoV-2 infection?", "ideal": "Yes, reinfection with SARS-CoV-2 is possible. Studies have shown that reinfection can occur within a few months of initial infection, although the risk of reinfection is low. Immunity to the virus is not guaranteed, and people who have had the virus should still take precautions to protect themselves and others from infection.", "exacta": "Yes", "clave": "1. SARS-CoV-2\n2. Reinfection\n3. Antibody\n4. Immune Response\n5. Viral Shedding\n6. Viral Load\n7. Neutralizing Antibody\n8. Seroconversion\n9. Antigenic Drift\n10. Viral Mutations", "short": "Yes, reinfection with SARS-CoV-2 is possible, although it is rare. Reinfection is more likely to occur in people with weakened immune systems."}, {"id": "644009c557b1c7a315000041", "type": "factoid", "body": "What is the mode of inheritance of Friedreich\u2019s ataxia?", "ideal": "Friedreich's ataxia is an inherited disorder caused by a mutation in the FXN gene. It is an autosomal recessive disorder, meaning that an individual must inherit two mutated copies of the gene, one from each parent, in order to develop the disorder.", "exacta": ["Friedreich's Ataxia", "Autosomal Recessive Inheritance", "Genetic Disorder", "Genetic Mutations", "Genes"], "clave": "1. Autosomal Recessive \n2. GAA Expansion \n3. Frataxin \n4. Mitochondrial DNA \n5. Spinocerebellar Ataxia \n6. Neurodegenerative Disease \n7. Chromosome 9 \n8. Hereditary Ataxia \n9. Nucleotide Repeat Expansion \n10. X-Linked Inheritance", "short": "Friedreich's ataxia is an autosomal recessive disorder, meaning that it is inherited when both copies of a gene are mutated."}, {"id": "641790a3690f196b5100002c", "type": "summary", "body": "What is the difference between Duchenne muscular Dystrophy and Becker muscular dystrophy?", "ideal": "Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are both genetic disorders that cause progressive muscle weakness and wasting. DMD is caused by a mutation in the dystrophin gene, while BMD is caused by a mutation in the dystrophin-related gene. DMD is more severe and progresses more quickly than BMD, and is usually diagnosed in childhood. BMD is usually diagnosed in adolescence or adulthood, and progresses more slowly.", "exacta": "", "clave": "Duchenne Muscular Dystrophy:\n-X-linked recessive inheritance\n-Dystrophin gene mutation\n-Early onset\n-Rapidly progressive\n-Complete absence of dystrophin\n\nBecker Muscular Dystrophy:\n-X-linked recessive inheritance\n-Dystrophin gene mutation\n-Later onset\n-Slowly progressive\n-Partial absence of dystrophin", "short": "Duchenne muscular dystrophy is a more severe form of muscular dystrophy that affects mostly males and begins in early childhood. Becker muscular dystrophy is a milder form that can affect both males and females and usually begins"}, {"id": "63f56dc533942b094c000001", "type": "summary", "body": "What is Lance-Adams syndrome?", "ideal": "Lance-Adams syndrome is a rare neurological disorder that affects the central nervous system. It is characterized by a combination of myoclonic jerks, ataxia, and cognitive impairment. It is caused by a mutation in the SCN1A gene, which is responsible for the production of a sodium channel protein. Symptoms usually begin in infancy or early childhood and can include seizures, developmental delays, and difficulty with coordination and balance. Treatment typically involves medications to control seizures and physical and occupational therapy to help with coordination and balance.", "exacta": "", "clave": "1. X-linked myotubular myopathy \n2. Centronuclear myopathy \n3. Congenital muscular dystrophy \n4. Hypotonia \n5. Muscle weakness \n6. Respiratory failure \n7. Impaired swallowing \n8. Impaired speech \n9. Intellectual disability \n10. Facial weakness \n11. Scoliosis \n12. Contractures \n13. Cardiomyopathy \n14. Abnormal gait \n15. Abnormal reflexes", "short": "Lance-Adams syndrome is a rare neurological disorder caused by a brain injury that results in difficulty controlling voluntary movements. It is characterized by spasticity, ataxia, and dysarthria."}, {"id": "643def7057b1c7a31500003a", "type": "summary", "body": "What does mitapivat do?", "ideal": "Mitapivat is a medication used to treat type 2 diabetes. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released from the pancreas and decreasing the amount of sugar produced by the liver. Mitapivat also helps to reduce the risk of cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes.", "exacta": "", "clave": "Mitapivat is a drug used to treat type 2 diabetes. The related biomedical terms are: antidiabetic, hypoglycemic, glucose-lowering, insulin-sensitizing, glucagon-like peptide-1 receptor agonist, and sulfonylurea.", "short": "Mitapivat is a Finnish word meaning to share. It is used to describe the act of sharing experiences, knowledge, and resources with others."}, {"id": "64371a4257b1c7a315000029", "type": "factoid", "body": "In prokaryotes, functionally related genes are sometimes positioned adjacent to each other in the genome and can be under the control of the same regulatory machinery. What are these called?", "ideal": "These functionally related genes that are positioned adjacent to each other in the genome and under the control of the same regulatory machinery are called operons. Operons are a common feature of prokaryotic genomes and are important for the efficient regulation of gene expression.", "exacta": "1. Operons \n2. Co-regulated genes \n3. Transcriptional units \n4. Gene clusters \n5. Polycistronic mRNA", "clave": "The answer to the question is: operons. Related biomedical terms include: transcriptional regulation, promoter, operator, transcription factor, ribosome binding site, mRNA, and translation.", "short": "These genes are called operons and they are organized into transcriptional units that are regulated by a single promoter."}, {"id": "6440377c57b1c7a315000049", "type": "factoid", "body": "What is the active ingredient of Xipere?", "ideal": "Xipere is a natural insecticide made from the extract of the neem tree. The active ingredient in Xipere is azadirachtin, a naturally occurring compound found in the neem tree. Azadirachtin is a powerful insecticide that works by disrupting the growth and development of insects, making them unable to reproduce and eventually die. It is also an effective repellent, deterring insects from entering treated areas.", "exacta": ["Xipere", "Active Ingredient", "Chemical Compound", "Organic Compound", "Molecule"], "clave": "Answer: Xipere, Piperacillin, Beta-lactamase inhibitor, Antibiotic, Penicillin, Bactericidal.", "short": "The active ingredient of Xipere is a combination of two plant-based extracts, Piper nigrum and Piper longum, which have been used for centuries in traditional medicine to treat a variety of ailments."}, {"id": "64163568690f196b5100001b", "type": "list", "body": "What are the most common mutation locations in dystrophin gene in Duchenne muscular dystrophy?", "ideal": "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are exon deletions, which account for approximately 65-75% of all mutations. Point mutations, which are single nucleotide changes, account for approximately 10-15% of mutations, while duplications and other complex rearrangements account for the remaining 10-20%. Exon deletions are the most common type of mutation because they are the easiest to detect and are the most likely to cause a complete loss of dystrophin protein production.", "exacta": ["exon 51", "exon 45", "exon 44", "exon 50", "exon 53"], "clave": "Answer: Dystrophin, Duchenne Muscular Dystrophy, Exon, Intron, Frameshift Mutation, Point Mutation, Deletion, Duplication, Splice Site Mutation.", "short": "The most common mutation locations in the dystrophin gene in Duchenne muscular dystrophy are exon deletions and duplications, which account for approximately 65-75% of all mutations."}, {"id": "63ee5eeaf36125a426000002", "type": "yesno", "body": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?", "ideal": "Mutation of the ARTEMIS gene is associated with a rare genetic disorder known as severe combined immunodeficiency (SCID). SCID is a life-threatening condition that affects the body's ability to fight off infections. People with SCID have a defect in their immune system, which makes them highly susceptible to infections. Mutations in the ARTEMIS gene can cause a form of SCID known as Omenn syndrome, which is characterized by skin rashes, enlarged lymph nodes, and low levels of certain immune cells. Treatment for SCID typically involves a bone marrow transplant or gene therapy.", "exacta": "No", "clave": "1. ARTEMIS gene\n2. Severe Combined Immunodeficiency (SCID)\n3. Mutation\n4. Immunodeficiency\n5. Genetic Disorder\n6. Primary Immunodeficiency\n7. Hematopoietic Stem Cell Transplantation (HSCT)\n8. Gene Therapy\n9. Recombinant DNA Technology\n10. Autosomal Recessive Inheritance", "short": "Yes, mutation of the ARTEMIS gene can cause severe combined immunodeficiency (SCID), a rare genetic disorder that affects the body's ability to fight off infections."}, {"id": "640c821c201352f04a000023", "type": "yesno", "body": "Is Wilson's disease described as an iron storage disease?", "ideal": "Wilson's disease is an inherited disorder that affects the body's ability to regulate copper. It is caused by a mutation in the ATP7B gene, which is responsible for the production of a protein that helps regulate copper levels in the body. As a result, copper accumulates in the liver, brain, and other organs, leading to a variety of symptoms. It is not described as an iron storage disease, but rather as a copper storage disorder.", "exacta": "No", "clave": "1. Hepatolenticular degeneration \n2. Autosomal recessive disorder \n3. Copper metabolism disorder \n4. Kayser-Fleischer rings \n5. Ceruloplasmin deficiency \n6. Neurological symptoms \n7. Liver cirrhosis \n8. Tyrosinemia type II \n9. Hepatic copper accumulation \n10. ATP7B gene mutation", "short": "No, Wilson's disease is not an iron storage disease. It is an inherited disorder that causes copper to build up in the body, leading to organ damage."}, {"id": "643c9b4057b1c7a315000032", "type": "summary", "body": "What are promoters?", "ideal": "Promoters are molecules that bind to specific sites on DNA and increase the rate of transcription of a gene. They are usually located upstream of the gene they regulate and can be either naturally occurring or artificially created. Promoters are essential for gene expression and can be used to control the expression of a gene in a cell.", "exacta": "", "clave": "Promoters: Transcription Factor, Enhancer, Promoter Element, Core Promoter, Upstream Regulatory Element, Transcriptional Activator, Transcriptional Repressor, Transcriptional Initiation Site, Transcriptional Start Site, Transcriptional Termination Site, Transcriptional Enhancer Element, Transcriptional Silencer Element, Transcriptional Regulatory Element, Transcriptional Regulatory Network, Transcriptional Regulatory Complex, Transcriptional Regulatory Pathway, Transcriptional Regulatory Cascade.", "short": "Promoters are regulatory regions of DNA that control the expression of genes. They are located upstream of the gene and bind transcription factors to initiate transcription."}, {"id": "6440084357b1c7a31500003e", "type": "yesno", "body": "Is omaveloxolone an activator of NFkB?", "ideal": "Omaveloxolone is a small molecule that has been shown to activate the transcription factor NF-kB, which is involved in the regulation of inflammation and immune responses. Omaveloxolone has been studied in preclinical models of inflammatory and autoimmune diseases, and has been shown to reduce inflammation and improve clinical outcomes. It is currently being evaluated in clinical trials for the treatment of several diseases.", "exacta": "No", "clave": "1. Omaveloxolone\n2. NF-kB\n3. Transcription Factor\n4. Nuclear Factor\n5. Inhibitor\n6. Activator\n7. Cytokine\n8. Inflammation\n9. Signal Transduction\n10. Protein Kinase", "short": "No, omaveloxolone is not an activator of NFkB. It is an inhibitor of NFkB, meaning it reduces the activity of NFkB."}, {"id": "6441057657b1c7a315000052", "type": "factoid", "body": "What is the most commonly used pain scale for the measurement of pain in children?", "ideal": "The most commonly used pain scale for the measurement of pain in children is the Faces Pain Scale-Revised (FPS-R). The FPS-R is a self-report scale that uses six cartoon faces to represent different levels of pain intensity. It is designed to be used by children aged 3-7 years old and is widely used in clinical settings to assess pain in children.", "exacta": "1. Numerical Rating Scale (NRS) \n2. Faces Pain Scale-Revised (FPS-R) \n3. Wong-Baker FACES Pain Rating Scale \n4. Visual Analogue Scale (VAS) \n5. Color Analog Scale (CAS)", "clave": ".\n\n1. Numerical Rating Scale (NRS)\n2. Pediatric Pain Scale\n3. Visual Analogue Scale (VAS)\n4. Faces Pain Scale\n5. Wong-Baker FACES Pain Rating Scale\n6. FLACC Scale\n7. Pain Intensity Scale\n8. Pain Assessment Tool\n9. Pain Severity Scale\n10. Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)", "short": "The most commonly used pain scale for children is the Faces Pain Scale-Revised (FPS-R). It is a visual scale that uses six cartoon faces to represent different levels of pain intensity."}, {"id": "6402c71f201352f04a00000a", "type": "summary", "body": "What is the mechanism of action of daridorexant?", "ideal": "Daridorexant is a dual orexin receptor antagonist, meaning it blocks the activity of orexin receptors in the brain. Orexin receptors are involved in the regulation of wakefulness and sleep, and by blocking their activity, daridorexant helps to promote sleep. It is thought to work by reducing wake-promoting signals in the brain, allowing for more restful sleep.", "exacta": "", "clave": "1. Hypocretin Receptor Agonist\n2. Orexin Receptor Antagonist\n3. Neuropeptide Receptor Modulator\n4. Dual Orexin Receptor Agonist/Antagonist\n5. Hypothalamic Orexinergic System\n6. Hypothalamic-Pituitary-Adrenal Axis\n7. Neurotransmitter Homeostasis\n8. Sleep-Wake Cycle Regulation\n9. Neuroendocrine Regulation\n10. Neurochemical Pathways", "short": "Daridorexant works by blocking the action of orexin, a neurotransmitter involved in wakefulness, and increasing the action of GABA, a neurotransmitter involved in sleep. This helps to promote sleep and reduce wakefulness."}, {"id": "64257c9c690f196b5100004b", "type": "factoid", "body": "What is DILI-CAT used for?", "ideal": "DILI-CAT (Drug-Induced Liver Injury Clinical Assessment Tool) is a tool used to assess the risk of drug-induced liver injury in patients. It is a validated, evidence-based tool that combines clinical, laboratory, and imaging data to provide a comprehensive assessment of the risk of drug-induced liver injury. It is used to help clinicians make informed decisions about the safety of medications and to identify patients at risk for drug-induced liver injury.", "exacta": ["Drug-Induced Liver Injury", "Clinical Assessment Tool", "Hepatotoxicity", "Liver Injury", "Drug Safety"], "clave": "DILI-CAT: Drug-Induced Liver Injury Clinical Assessment Tool\n\nBiomedical Terms:\nHepatotoxicity, Drug-Induced Liver Injury, Liver Injury, Liver Function Tests, Liver Biopsy, Serum Alanine Aminotransferase, Serum Aspartate Aminotransferase, Serum Alkaline Phosphatase, Serum Bilirubin, Serum Albumin, Prothrombin Time, International Normalized Ratio, Clinical Assessment Tool.", "short": "DILI-CAT is a computer-based tool used to assess the risk of drug-induced liver injury. It uses a combination of patient characteristics, drug characteristics, and laboratory values to predict the likelihood of liver injury."}, {"id": "6429e1b857b1c7a315000008", "type": "summary", "body": "What is the significance of a persistently positive RT-PCR for weeks after illness?", "ideal": "A persistently positive RT-PCR test result for weeks after illness can indicate that the virus is still present in the body and that the person is still contagious. It can also indicate that the person has a chronic infection, which can lead to long-term health complications. It is important to seek medical advice if a person has a persistently positive RT-PCR test result for weeks after illness.", "exacta": "", "clave": "1. Reverse Transcription Polymerase Chain Reaction (RT-PCR)\n2. Viral Shedding\n3. Viral Load\n4. Viral Persistence\n5. Viral Replication\n6. Viral Genome\n7. Viral Infection\n8. Viral Antigen\n9. Viral Proteins\n10. Viral Pathogenesis", "short": "A persistently positive RT-PCR for weeks after illness may indicate that the virus is still present in the body, and that the person may still be contagious."}, {"id": "644029f857b1c7a315000042", "type": "summary", "body": "What is the genetic cause of Freidreichs ataxia?", "ideal": "Freidreich's ataxia is a rare, inherited, progressive neurological disorder caused by a mutation in the FXN gene. This gene is responsible for producing frataxin, a protein that is essential for the normal functioning of the nervous system. The lack of frataxin leads to damage to the nervous system, resulting in a wide range of symptoms including ataxia, muscle weakness, vision and hearing loss, and heart problems.", "exacta": "", "clave": "1. Friedreich's Ataxia\n2. GAA Expansion\n3. Frataxin\n4. Autosomal Recessive Inheritance\n5. X25 Gene\n6. Mitochondrial Dysfunction\n7. Spinocerebellar Ataxia\n8. Neurodegeneration\n9. Cardiomyopathy\n10. Iron Accumulation", "short": "Freidreich's ataxia is caused by a mutation in the FXN gene, which leads to a deficiency of the protein frataxin."}, {"id": "6442869857b1c7a31500005d", "type": "list", "body": "Which diagnostic tests are used for the diagnosis of FSHD?", "ideal": "FSHD (facioscapulohumeral muscular dystrophy) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. Diagnosis of FSHD is typically done through a combination of physical examination, family history, and genetic testing. Commonly used diagnostic tests include electromyography (EMG), muscle biopsy, and genetic testing for the FSHD1 gene. Other tests such as imaging studies, blood tests, and nerve conduction studies may also be used to help diagnose FSHD.", "exacta": ["FSHD Genetic Test", "EMG Test", "MRI Test"], "clave": "1. Electromyography (EMG)\n2. Magnetic Resonance Imaging (MRI)\n3. Genetic Testing\n4. Muscle Biopsy\n5. Facioscapulohumeral Dystrophy (FSHD)\n6. D4Z4 Deletion\n7. Chromosome 4q35 Deletion\n8. Myotonic Dystrophy Type 1 (DM1)\n9. Myotonic Dystrophy Type 2 (DM2)\n10. Dysferlin Protein Deficiency", "short": "Diagnosis of FSHD typically involves a physical exam, genetic testing, and electromyography (EMG). EMG is used to measure the electrical activity of muscles and can detect abnormal muscle activity."}, {"id": "64040d73201352f04a000010", "type": "yesno", "body": "Can Efgartigimod be used for myasthenia gravis?", "ideal": "Efgartigimod is a monoclonal antibody that has been approved by the FDA for the treatment of myasthenia gravis, an autoimmune disorder that affects the neuromuscular junction. It works by binding to the B-cell surface antigen CD3, which helps to reduce the production of autoantibodies that attack the neuromuscular junction. Clinical trials have shown that Efgartigimod can reduce the severity of symptoms and improve quality of life in patients with myasthenia gravis.", "exacta": "No", "clave": ".\n\nMyasthenia Gravis, Efgartigimod, Autoimmune Disease, Neuromuscular Junction, Acetylcholine Receptor, Immunomodulatory Therapy, Neostigmine, Corticosteroids.", "short": "No, efgartigimod is not approved for the treatment of myasthenia gravis. It is an investigational drug being studied for the treatment of autoimmune diseases."}, {"id": "6422e7ba690f196b51000044", "type": "yesno", "body": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier", "ideal": "?\n\nRecent studies have shown that Quercetin-biapigenin nanoparticles have the potential to penetrate the blood-brain barrier, which could be beneficial for drug delivery to the brain. In vitro studies have demonstrated that these nanoparticles can effectively cross the blood-brain barrier, and in vivo studies have shown that they can be used to deliver drugs to the brain with minimal toxicity. Further research is needed to determine the efficacy of these nanoparticles in clinical settings.", "exacta": "?", "clave": "Blood-Brain Barrier, Quercetin, Biapigenin, Nanoparticles, Drug Delivery, Brain Targeting, Brain Uptake, Brain Distribution, Brain Penetration, Brain Accumulation.", "short": "Yes, quercetin-biapigenin nanoparticles have been shown to be effective in penetrating the blood-brain barrier. They have been found to increase the delivery of drugs to the brain, potentially improving treatment of neurological diseases."}, {"id": "6429e85e57b1c7a315000009", "type": "factoid", "body": "What process involves metabolite-sensing mRNAs to control gene expression?", "ideal": "Metabolite-sensing mRNAs are a type of regulatory RNA that can detect changes in the levels of metabolites in the cell and use this information to control gene expression. This process involves the binding of metabolites to the mRNA, which then triggers a cascade of events that leads to the activation or repression of gene expression. This type of regulation is important for maintaining homeostasis in the cell and is essential for proper cellular functioning.", "exacta": "1. mRNA \n2. Metabolite \n3. Gene Expression \n4. Metabolite-Sensing \n5. Control", "clave": "1. Post-transcriptional regulation\n2. Metabolite-sensing mRNAs\n3. mRNA stability\n4. Translational control\n5. MicroRNA-mediated silencing\n6. Target mRNA degradation\n7. Transcriptional attenuation\n8. Translational repression\n9. mRNA decay pathways\n10. RNA-binding proteins", "short": "The process of metabolite-sensing mRNAs controlling gene expression involves mRNAs that are sensitive to metabolites binding to regulatory proteins, which then modulate the expression of target genes."}, {"id": "6440360557b1c7a315000047", "type": "summary", "body": "What is Concerta\u00ae?", "ideal": "Concerta\u00ae is a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adults. It is a long-acting form of methylphenidate, a stimulant medication that works by increasing the levels of dopamine and norepinephrine in the brain. Concerta\u00ae is taken once daily and can help improve focus, concentration, and impulse control in people with ADHD.", "exacta": "", "clave": "1. Methylphenidate\n2. Central Nervous System Stimulant\n3. ADHD\n4. Extended-Release Formulation\n5. Psychostimulant\n6. Monoamine Reuptake Inhibitor\n7. Neurotransmitter Modulation\n8. Osmotic-Release Oral System (OROS)\n9. Methylphenidate Hydrochloride\n10. Attention Deficit Hyperactivity Disorder (ADHD)", "short": "Concerta\u00ae is a prescription medication used to treat attention deficit hyperactivity disorder (ADHD). It is a long-acting form of methylphenidate, a stimulant medication."}, {"id": "641794e7690f196b51000036", "type": "list", "body": "What are the most common neuropsychiatric disorders associated with Duchenne muscular dystrophy?", "ideal": "Duchenne muscular dystrophy (DMD) is a genetic disorder that affects the muscles and is associated with a range of neuropsychiatric disorders. The most common neuropsychiatric disorders associated with DMD include anxiety, depression, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability. Other conditions such as sleep disturbances, aggression, and impulsivity may also be present. Treatment for these conditions typically involves a combination of medication, psychotherapy, and lifestyle modifications.", "exacta": ["Depression", "Anxiety", "Attention Deficit Hyperactivity Disorder (ADHD)", "Behavioral Problems", "Learning Disabilities"], "clave": "1. Dystrophinopathy\n2. Cognitive Impairment\n3. Attention Deficit Hyperactivity Disorder (ADHD)\n4. Anxiety Disorders\n5. Depression\n6. Autistic Spectrum Disorders\n7. Obsessive Compulsive Disorder (OCD)\n8. Behavioral Problems\n9. Learning Disabilities\n10. Sleep Disturbances", "short": "The most common neuropsychiatric disorders associated with Duchenne muscular dystrophy are anxiety, depression, attention deficit hyperactivity disorder (ADHD), and autism spectrum disorder (ASD)."}, {"id": "63ee5c78f36125a426000001", "type": "list", "body": "Which interleukins are affected by Dupilumab?", "ideal": "Dupilumab is a monoclonal antibody that targets the IL-4 receptor alpha subunit, which is involved in the signaling of two interleukins, IL-4 and IL-13. By blocking the IL-4 receptor alpha subunit, Dupilumab reduces the activity of both IL-4 and IL-13, resulting in decreased inflammation and improved symptoms of asthma and atopic dermatitis.", "exacta": ["Interleukin-4", "Interleukin-13"], "clave": "Answer: Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-13 (IL-13), Dupilumab, Th2-mediated inflammation, Eosinophilic inflammation, Atopic dermatitis.", "short": "Dupilumab affects interleukins IL-4 and IL-13, which are involved in the body's allergic response. It works by blocking the action of these interleukins, reducing inflammation and symptoms of allergic diseases"}, {"id": "64316f8e57b1c7a315000016", "type": "list", "body": "What cells are used to regenerate cartilage?", "ideal": "Cartilage is a type of connective tissue found in many parts of the body, including the joints. It is composed of specialized cells called chondrocytes, which are responsible for the production and maintenance of the cartilage matrix. Chondrocytes are also capable of regenerating cartilage, which is important for the repair of damaged cartilage. This process is known as chondrogenesis, and involves the proliferation and differentiation of chondrocytes into mature cartilage cells.", "exacta": ["Chondrocytes"], "clave": "Answer: Chondrocytes, Chondrogenesis, Mesenchymal Stem Cells, Hyaline Cartilage, Extracellular Matrix, Proteoglycans, Collagen.", "short": "Chondrocytes are the cells used to regenerate cartilage. They are responsible for the production and maintenance of the extracellular matrix, which is the main component of cartilage."}, {"id": "6429eb8457b1c7a31500000a", "type": "yesno", "body": "Is adenosine methylation an epigenetic modification?", "ideal": "Adenosine methylation is an epigenetic modification, which is a type of post-translational modification that affects gene expression without changing the underlying DNA sequence. It is a reversible process that involves the addition of a methyl group to the adenosine base of DNA or RNA molecules, which can alter gene expression and influence the development of cells and organisms. Adenosine methylation is involved in a variety of biological processes, including gene regulation, chromatin remodeling, and DNA repair.", "exacta": "Yes", "clave": "Epigenetic Modification: DNA Methylation, Histone Modification, Chromatin Remodeling, Non-coding RNA, DNA Methyltransferase, Histone Acetyltransferase, Histone Deacetylase, Chromatin-Associated Proteins, Chromatin-Remodeling Complexes, DNA Methylation Profiling, Histone Modification Profiling.", "short": "Yes, adenosine methylation is an epigenetic modification. It is a chemical process that alters gene expression without changing the underlying DNA sequence."}, {"id": "6440393157b1c7a31500004a", "type": "factoid", "body": "Which year was XIPERE approved by the FDA?", "ideal": "XIPERE (sodium zirconium cyclosilicate) was approved by the U.S. Food and Drug Administration (FDA) in 2018 as a treatment for hyperkalemia, a condition characterized by elevated levels of potassium in the blood. It is the first and only FDA-approved treatment for this condition.", "exacta": ["FDA", "XIPERE", "Food and Drug Administration", "US Food and Drug Administration", "US FDA"], "clave": ".\n\n1. XIPERE \n2. FDA \n3. Regulatory Approval \n4. Drug Development \n5. Clinical Trials \n6. Pharmaceuticals \n7. Biopharmaceuticals \n8. Investigational New Drug Application \n9. New Drug Application \n10. Pre-Market Approval", "short": "XIPERE was approved by the FDA in 2019. It is a drug used to treat adults with type 2 diabetes, helping to lower blood sugar levels and reduce the risk of major cardiovascular events."}, {"id": "64412c2757b1c7a315000055", "type": "yesno", "body": "Can breastfeeding be used to alleviate the procedural pain in neonates?", "ideal": "Breastfeeding has been found to be an effective way to reduce the pain experienced by neonates during medical procedures. Studies have shown that breastfeeding during a procedure can reduce the amount of pain experienced by the infant, as well as reduce the amount of time it takes for the infant to recover from the procedure. Breastfeeding can also help to reduce the amount of stress experienced by the infant, as well as the amount of stress experienced by the parents.", "exacta": "Yes", "clave": "1. Neonatal Pain\n2. Breastfeeding\n3. Procedural Pain\n4. Analgesia\n5. Neonatal Analgesia\n6. Non-pharmacological Analgesia\n7. Maternal-Infant Bonding\n8. Neonatal Stress Response\n9. Neonatal Neurodevelopmental Outcomes\n10. Neonatal Neurobehavioral Outcomes", "short": "Yes, breastfeeding can be used to reduce the pain of procedures in neonates. It has been shown to reduce pain scores, heart rate, and cortisol levels."}, {"id": "64042000201352f04a000020", "type": "yesno", "body": "Can lenacapavir be used for HIV?", "ideal": "Lenacapavir is a new antiviral drug that is being studied as a potential treatment for HIV. It is a capsid inhibitor, meaning it works by blocking the virus from entering and replicating in human cells. In clinical trials, lenacapavir has been shown to reduce the amount of HIV in the body and improve the immune system's ability to fight the virus. It is not yet approved for use in humans, but it is being studied as a potential treatment for HIV.", "exacta": "No", "clave": "1. Lenacapavir\n2. HIV\n3. Antiretroviral Therapy\n4. Protease Inhibitor\n5. Integrase Inhibitor\n6. Reverse Transcriptase Inhibitor\n7. Post-Exposure Prophylaxis\n8. Pre-Exposure Prophylaxis\n9. Viral Load\n10. CD4 Count", "short": "No, lenacapavir is not used to treat HIV. It is an antiviral medication used to treat chronic hepatitis B virus infection."}, {"id": "6415b3b4690f196b51000009", "type": "factoid", "body": "What color light does the the inhibitory receptor halorhodopsin (eNpHR) respond to?", "ideal": "Halorhodopsin (eNpHR) is an inhibitory receptor that responds to yellow-green light (wavelength of 568 nm). It is a light-activated chloride ion channel found in halobacteria, which are a type of extremophile bacteria that live in highly salty environments. eNpHR is used in optogenetics, a field of neuroscience that uses light to control neurons.", "exacta": ["Blue Light", "Violet Light", "Ultraviolet Light", "Indigo Light", "Green Light"], "clave": "1. Halorhodopsin\n2. eNpHR\n3. Inhibitory Receptor\n4. Chloride Ion\n5. Phototransduction\n6. Retinal Chromophore\n7. Infrared Light\n8. Membrane Potential\n9. Hyperpolarization", "short": "Halorhodopsin (eNpHR) responds to yellow-green light, specifically wavelengths between 500-550 nm."}, {"id": "6429fad757b1c7a31500000e", "type": "factoid", "body": "What regulatory element promotes RNA polymerase II binding as well as the binding of factors that facilitate the unwinding of DNA prior to translation?", "ideal": "The regulatory element that promotes RNA polymerase II binding and the binding of factors that facilitate the unwinding of DNA prior to translation is the TATA box. The TATA box is a short sequence of DNA located near the start of a gene that binds to the transcription factor TFIID, which in turn binds to RNA polymerase II and other transcription factors. This binding helps to initiate transcription and allows for the unwinding of DNA prior to translation.", "exacta": "Answer: \n1. TATA box \n2. Initiator element \n3. CAAT box \n4. GC box \n5. BRE element", "clave": "1. TATA box\n2. Transcription factor\n3. Promoter\n4. Transcription initiation complex\n5. RNA polymerase II\n6. DNA unwinding\n7. Pre-initiation complex\n8. Core promoter elements", "short": "The TATA box is a regulatory element that promotes RNA polymerase II binding and the binding of factors that facilitate the unwinding of DNA prior to translation."}, {"id": "64402e7757b1c7a315000044", "type": "factoid", "body": "How many patients with Friedreich's ataxia were included in each cohort of the phase I/II double-blind, comparator-controlled trial of RT001.", "ideal": "The phase I/II double-blind, comparator-controlled trial of RT001 included a total of 48 patients with Friedreich's ataxia, divided into two cohorts of 24 patients each. The trial was designed to evaluate the safety, tolerability, and efficacy of RT001 in patients with Friedreich's ataxia.", "exacta": "1. RT001 \n2. Friedreich's Ataxia \n3. Phase I/II Double-Blind \n4. Comparator-Controlled Trial \n5. Patients", "clave": "Friedreich's ataxia, phase I/II clinical trial, double-blind, comparator-controlled, RT001, patient cohort, neurological disorder, neuromuscular degeneration.", "short": "A total of 24 patients with Friedreich's ataxia were included in the trial, 12 in each cohort."}, {"id": "64425ce357b1c7a315000059", "type": "factoid", "body": "What is the incidence of Facioscapulohumeral Muscular Dystrophy?", "ideal": "Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. It is estimated to affect 1 in 8,000 to 1 in 20,000 people worldwide, with a higher prevalence in certain populations. FSHD is an autosomal dominant disorder, meaning that it is inherited from a parent who has the disorder. Symptoms of FSHD can vary from person to person, but typically include muscle weakness, wasting, and contractures.", "exacta": ["Facioscapulohumeral Muscular Dystrophy", "FSHD", "Muscular Dystrophy", "Duchenne Muscular Dystrophy", "Myotonic Dystrophy"], "clave": "1. Facioscapulohumeral Muscular Dystrophy (FSHD)\n2. Myogenic\n3. Autosomal Dominant\n4. Chromosome 4q35\n5. D4Z4\n6. Dysarthria\n7. Myopathy\n8. Weakness\n9. Contractures\n10. Scapular Winging", "short": "Facioscapulohumeral Muscular Dystrophy (FSHD) affects approximately 1 in 8,000 to 1 in 20,000 people worldwide."}, {"id": "63f581e933942b094c000007", "type": "factoid", "body": "Risdiplam is used for treatment of which disease?", "ideal": "Risdiplam is a medication used to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects the muscles used for movement. It is a type of antisense oligonucleotide (ASO) therapy, which works by targeting the genetic cause of SMA and restoring the production of a protein called survival motor neuron (SMN). Risdiplam is approved for use in people aged 2 months and older with SMA types 1, 2, 3, and 4.", "exacta": ["Spinal Muscular Atrophy", "Amyotrophic Lateral Sclerosis", "Motor Neuron Disease", "Muscular Dystrophy", "Multiple Sclerosis"], "clave": "1. Spinal Muscular Atrophy (SMA)\n2. Risdiplam\n3. SMN2 gene\n4. Survival Motor Neuron (SMN) protein\n5. Motor neuron degeneration\n6. Neuromuscular disorder\n7. Motor neuron dysfunction\n8. Motor neuron disease\n9. Neuromuscular junction\n10. Neuromuscular junction impairment", "short": "Risdiplam is used to treat spinal muscular atrophy (SMA), a genetic disorder that affects muscle strength and movement. It works by increasing the production of a protein that helps preserve and improve muscle function."}, {"id": "641c5201690f196b51000040", "type": "list", "body": "Please list the diseases associated with elevations in the plasma Neurofilament Light chain (NfL).", "ideal": "Neurofilament Light chain (NfL) is a protein found in the axons of neurons and is used as a biomarker for neurological diseases. Elevations in NfL have been associated with a variety of neurological diseases, including multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and stroke. Additionally, NfL has been linked to other neurological conditions such as epilepsy, migraine, and neuropathy.", "exacta": ["Amyotrophic Lateral Sclerosis", "Multiple Sclerosis", "Alzheimer's Disease", "Parkinson's Disease", "Traumatic Brain Injury"], "clave": "1. Neurofilament Light Chain (NfL) Elevation \n2. Amyotrophic Lateral Sclerosis (ALS) \n3. Multiple Sclerosis (MS) \n4. Motor Neuron Disease (MND) \n5. Spinal Muscular Atrophy (SMA) \n6. Primary Lateral Sclerosis (PLS) \n7. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) \n8. Guillain-Barre Syndrome (GBS) \n9. Traumatic Brain Injury (TBI) \n10. Huntington's Disease (HD)", "short": "The diseases associated with elevations in the plasma Neurofilament Light chain (NfL) include multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and stroke."}, {"id": "643c183b57b1c7a31500002c", "type": "list", "body": "What are the most common assays to profile chromatin accessibility?", "ideal": "Chromatin accessibility assays are laboratory techniques used to measure the degree to which DNA is accessible to transcription factors and other proteins. The most common assays used to profile chromatin accessibility are DNase-seq, ATAC-seq, FAIRE-seq, and ChIP-seq. These assays measure the accessibility of DNA by measuring the amount of DNA that is digested by DNase, the amount of DNA that is bound by transcription factors, or the amount of DNA that is open to transcription.", "exacta": ["DNase-seq", "FAIRE-seq", "ATAC-seq"], "clave": "ChIP-seq, DNase-seq, ATAC-seq, FAIRE-seq, MNase-seq, ChIP-exo, ChIPmentation, DamID, CUT&RUN, CUT&Tag, ChIA-PET, HiChIP, ChIP-RX, ChIP-nexus.", "short": "The most common assays to profile chromatin accessibility are DNase-seq, ATAC-seq, and FAIRE-seq. These assays measure the accessibility of DNA to enzymes that cut it, allowing for the identification of open chrom"}, {"id": "64402f6f57b1c7a315000045", "type": "list", "body": "What doses of RT001 were used in the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients?", "ideal": "In the phase I/II double-blind, comparator-controlled trial of Friedreich's ataxia patients, two doses of RT001 were used: a low dose of 0.5 mg/kg and a high dose of 1.5 mg/kg. The trial was designed to assess the safety, tolerability, and efficacy of RT001 in patients with Friedreich's ataxia.", "exacta": ["2mg", "4mg", "6mg", "8mg"], "clave": ".\n\n-Friedreich's Ataxia\n-Phase I/II Clinical Trial\n-Double-Blind\n-Comparator-Controlled\n-RT001 Dose", "short": "The phase I/II trial used two doses of RT001: a low dose of 0.5 mg/kg and a high dose of 1.0 mg/kg. Both doses were administered intravenously every two weeks for 24 weeks."}, {"id": "6440f85c57b1c7a315000051", "type": "list", "body": "What are the most common pain scales used to measure pain in neonates?", "ideal": "Pain scales are used to measure pain in neonates, or newborns. The most common pain scales used are the Premature Infant Pain Profile (PIPP), the Neonatal Infant Pain Scale (NIPS), the CRIES scale, and the Face, Legs, Activity, Cry, Consolability (FLACC) scale. Each of these scales assesses different aspects of pain, such as facial expressions, body movements, and vocalizations. They are used to help healthcare providers accurately assess and manage pain in neonates.", "exacta": ["Numeric Pain Scale", "Neonatal Facial Coding System", "Neonatal Infant Pain Scale", "Premature Infant Pain Profile"], "clave": "Neonatal Pain Scale, Premature Infant Pain Profile, CRIES Scale, Neonatal Facial Coding System, Neonatal Behavioral Assessment Scale, Neonatal Abstinence Syndrome Score, Neonatal Pain, Agitation and Sedation Scale, Neonatal Neurobehavioral Scale, Neonatal Intensive Care Unit Network Neurobehavioral Scale.", "short": "The most common pain scales used to measure pain in neonates are the Premature Infant Pain Profile (PIPP), the Neonatal Infant Pain Scale (NIPS), and the CRIES scale."}, {"id": "6402c3fd201352f04a000009", "type": "yesno", "body": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?", "ideal": "The RIGHT-2 trial was a randomized, double-blind, placebo-controlled trial that evaluated the effectiveness of prehospital transdermal glyceryl trinitrate (GTN) for stroke. The results of the trial showed that prehospital GTN was not effective in improving outcomes for stroke patients, with no significant differences in mortality or disability between the GTN and placebo groups.", "exacta": "No", "clave": "1. Prehospital \n2. Transdermal \n3. Glyceryl Trinitrate \n4. Stroke \n5. RIGHT-2 Trial \n6. Cerebrovascular Accident \n7. Ischemic Stroke \n8. Acute Stroke \n9. Thrombolysis \n10. Neuroprotection", "short": "Yes, prehospital transdermal glyceryl trinitrate was effective for stroke in the RIGHT-2 trial. The trial showed a significant reduction in disability at 90 days compared to placebo."}, {"id": "6431f7de57b1c7a31500001b", "type": "factoid", "body": "What gene is mutated in Friedreich's ataxia?", "ideal": "Friedreich's ataxia is a rare, inherited neurological disorder caused by a mutation in the FXN gene. This gene is responsible for producing frataxin, a protein that is essential for the normal functioning of cells in the body. The mutation in the FXN gene leads to a decrease in the amount of frataxin produced, which causes the symptoms of Friedreich's ataxia.", "exacta": ["Friedreich Ataxia", "FXN", "FRDA", "GAA", "FXN gene"], "clave": "Friedreich's ataxia, FXN gene, frataxin protein, GAA triplet repeat expansion, autosomal recessive inheritance, spinocerebellar ataxia.", "short": "The gene mutated in Friedreich's ataxia is the FXN gene, which encodes frataxin, a protein involved in iron metabolism."}, {"id": "643ff48a57b1c7a31500003d", "type": "yesno", "body": "Is omaveloxolone a suppressor of Nrf2?", "ideal": "Omaveloxolone is a small molecule that has been shown to be a potent suppressor of Nrf2, a transcription factor that plays a role in the regulation of antioxidant and cytoprotective genes. Omaveloxolone has been shown to reduce Nrf2 activity in a dose-dependent manner, leading to decreased expression of Nrf2-regulated genes and decreased antioxidant and cytoprotective activity.", "exacta": "No", "clave": "1. Omaveloxolone \n2. Nrf2 \n3. Oxidative Stress \n4. Antioxidant \n5. Endoplasmic Reticulum Stress \n6. Keap1 \n7. Glutathione \n8. Nuclear Factor Erythroid 2-Related Factor 2 \n9. Cytoprotection \n10. Autophagy", "short": "No, omaveloxolone is not a suppressor of Nrf2. It is an activator of Nrf2, which helps to protect cells from oxidative stress."}, {"id": "64410f8057b1c7a315000054", "type": "yesno", "body": "Can salivary cortisol be used to evaluate pain in neonates?", "ideal": "Salivary cortisol is a hormone that is released in response to stress, and can be used to evaluate pain in neonates. Studies have shown that salivary cortisol levels increase in response to painful stimuli in neonates, and can be used to measure the intensity of pain experienced. This method of pain assessment is non-invasive and can provide a more accurate measure of pain than other methods.", "exacta": "No", "clave": "1. Neonates\n2. Salivary Cortisol\n3. Pain\n4. Biomarker\n5. Stress Response\n6. Infants\n7. Non-Invasive\n8. Neuroendocrine\n9. Analgesia\n10. Physiological Measurement", "short": "No, salivary cortisol cannot be used to evaluate pain in neonates. It is not a reliable measure of pain in this age group."}, {"id": "6402c0d5201352f04a000008", "type": "yesno", "body": "Does nintedanib improve response rate in patients with bladder cancer?", "ideal": "Nintedanib is a drug that has been studied for its potential to improve response rate in patients with bladder cancer. In a recent clinical trial, nintedanib was found to significantly improve response rate in patients with advanced bladder cancer, with a median response rate of 33.3%. Additionally, nintedanib was found to be well tolerated, with no serious adverse events reported. These results suggest that nintedanib may be a promising treatment option for patients with bladder cancer.", "exacta": "No", "clave": "1. Nintedanib\n2. Bladder Cancer\n3. Response Rate\n4. Chemotherapy\n5. Immunotherapy\n6. Targeted Therapy\n7. Cystectomy\n8. Radiotherapy\n9. Neoadjuvant Therapy\n10. Adjuvant Therapy", "short": "No, nintedanib does not improve response rate in patients with bladder cancer. Studies have shown that nintedanib does not improve overall survival or progression-free survival in this population."}, {"id": "6419fa3d690f196b5100003c", "type": "summary", "body": "What is the difference between siRNA and Antisense oligonucleotide therapeutics", "ideal": "?\n\nSmall interfering RNA (siRNA) and Antisense oligonucleotide (ASO) therapeutics are two types of RNA-based therapies used to treat genetic diseases. siRNA works by targeting and silencing specific messenger RNA (mRNA) molecules, while ASO works by binding to mRNA molecules and blocking their translation into proteins. Both therapies have been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders.", "exacta": "", "clave": "1. Small Interfering RNA (siRNA)\n2. Antisense Oligonucleotide (ASO)\n3. Gene Silencing\n4. RNA Interference (RNAi)\n5. Target mRNA\n6. Double-Stranded RNA (dsRNA)\n7. Sense Strand\n8. Antisense Strand\n9. Therapeutic Target\n10. Therapeutic Delivery", "short": "siRNA is a double-stranded RNA molecule that binds to and silences specific mRNA molecules, while antisense oligonucleotide therapeutics are single-stranded molecules that bind to and block the translation of mRNA."}, {"id": "644036cf57b1c7a315000048", "type": "summary", "body": "What is Yutiq?", "ideal": "Yutiq is a prescription eye medication used to treat chronic non-infectious uveitis, a condition that causes inflammation in the eye. It is a sustained-release, injectable form of the steroid fluocinolone acetonide, which helps reduce inflammation and pain. Yutiq is administered by a healthcare professional in a doctor's office or clinic. It is typically given as a single injection every three months, and can help improve vision and reduce the risk of complications from uveitis.", "exacta": "", "clave": "Answer: Yutiq is a brand of aqueous fluocinolone acetonide intravitreal implant, a type of medication used to treat chronic non-infectious uveitis. Related biomedical terms include: fluocinolone acetonide, intravitreal implant, uveitis, non-infectious, chronic, medication, aqueous.", "short": "Yutiq is a prescription eye drop that helps treat chronic non-infectious uveitis, a condition that can cause vision loss. It works by reducing inflammation and preventing further damage to the eye."}, {"id": "643f9eeb57b1c7a31500003c", "type": "factoid", "body": "What is the incidence of Duchenne Muscular Dystrophy?", "ideal": "Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder that affects approximately 1 in every 3,500 to 5,000 male births worldwide. It is caused by a mutation in the dystrophin gene, which results in progressive muscle weakness and loss of muscle mass. DMD is the most common form of muscular dystrophy in children, and it is usually diagnosed in early childhood. It is a progressive disorder, and there is currently no cure.", "exacta": ["Duchenne Muscular Dystrophy", "Muscular Dystrophy", "Duchenne", "Muscular Dystrophy Association", "DMD"], "clave": "1. Duchenne Muscular Dystrophy (DMD)\n2. X-linked recessive inheritance\n3. Dystrophin gene\n4. Dystrophin protein\n5. Muscular dystrophy-associated glycoproteins\n6. Dystrophic pathology\n7. Cardiomyopathy\n8. Respiratory insufficiency\n9. Muscular atrophy\n10. Contractures", "short": "Duchenne Muscular Dystrophy affects approximately 1 in 3,500 to 5,000 male births worldwide. It is the most common form of muscular dystrophy in children."}, {"id": "6402ba49201352f04a000004", "type": "list", "body": "Which drugs were studied in the TRICOTEL study?", "ideal": "The TRICOTEL study was a randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of three drugs: telmisartan, rosuvastatin, and a combination of both. The study included 1,845 patients with hypertension and dyslipidemia, and the primary outcome was the change in systolic blood pressure after 12 weeks of treatment.", "exacta": ["tacrolimus", "sirolimus"], "clave": "Answer: TRICOTEL study, anticoagulants, warfarin, dabigatran, rivaroxaban, apixaban, thromboembolic events, stroke, venous thromboembolism, atrial fibrillation.", "short": "The TRICOTEL study examined the effects of three drugs: telmisartan, ramipril, and rosuvastatin, on cardiovascular risk factors in patients with type 2 diabetes."}, {"id": "6431f6a857b1c7a315000018", "type": "summary", "body": "How is amniotic fluid produced?", "ideal": "Amniotic fluid is a clear, slightly yellowish liquid that surrounds and protects a developing fetus in the womb. It is produced by the fetus, the placenta, and the amniotic membrane. The fetus produces urine, which is the main component of amniotic fluid. The placenta produces hormones and other substances that are also found in the fluid. The amniotic membrane secretes a watery fluid that helps to cushion and protect the fetus.", "exacta": "", "clave": "1. Amniotic Sac\n2. Amniotic Cavity\n3. Fetal Membranes\n4. Chorionic Villi\n5. Uterine Wall\n6. Placental Exchange\n7. Fetal Urination\n8. Fetal Swallowing\n9. Fetal Respiration\n10. Fetal Metabolism", "short": "Amniotic fluid is produced by the fetal kidneys and lungs, and is also composed of water and proteins from the mother's blood, as well as cells from the fetus."}, {"id": "6415c252690f196b51000011", "type": "factoid", "body": "Which cancer is the BCG vaccine used for?", "ideal": "The BCG vaccine is used to prevent tuberculosis (TB) and is sometimes used to help prevent bladder and other urinary tract cancers. It is not a cancer vaccine, but it has been found to reduce the risk of bladder cancer in some people. It is most commonly used in countries with high rates of TB, but it is also used in some countries to help reduce the risk of bladder cancer.", "exacta": ["Bladder Cancer", "Lung Cancer", "Gastric Cancer", "Prostate Cancer", "Colorectal Cancer"], "clave": "1. Bladder Cancer \n2. Bacillus Calmette-Guerin (BCG) Vaccine \n3. Immunotherapy \n4. Intravesical Therapy \n5. Urothelial Carcinoma \n6. Carcinoma in Situ \n7. Superficial Bladder Tumors \n8. Non-Muscle Invasive Bladder Cancer \n9. Recurrent Bladder Cancer \n10. Chemotherapy", "short": "The BCG vaccine is used to prevent tuberculosis (TB) and is sometimes used to help prevent bladder and other types of urinary tract cancers."}, {"id": "641791b9690f196b51000030", "type": "list", "body": "What are the most common congenital muscular dystrophies?", "ideal": "Congenital muscular dystrophies (CMDs) are a group of inherited muscle diseases that are present at birth. They are caused by genetic mutations that affect the structure and function of the muscles. The most common CMDs include merosin-deficient CMD, laminin-alpha-2-deficient CMD, collagen VI-related CMD, and Fukuyama CMD. Symptoms vary depending on the type of CMD, but can include muscle weakness, joint contractures, and respiratory problems. Treatment focuses on managing symptoms and preventing complications.", "exacta": ["Duchenne Muscular Dystrophy", "Becker Muscular Dystrophy", "Congenital Muscular Dystrophy Type 1", "Congenital Muscular Dystrophy Type 2", "Limb-Girdle Muscular Dystrophy Type 1A", "Fukuyama Congenital Muscular Dystrophy"], "clave": "1. Duchenne Muscular Dystrophy \n2. Becker Muscular Dystrophy \n3. Limb-Girdle Muscular Dystrophy \n4. Congenital Myotonic Dystrophy \n5. Fukuyama Congenital Muscular Dystrophy \n6. Congenital Muscular Dystrophy with Merosin Deficiency \n7. Congenital Muscular Dystrophy with Rigid Spine Syndrome \n8. Congenital Muscular Dystrophy with Central Nervous System Involvement \n9. Congenital Muscular Dystrophy with Neurogenic Scoliosis \n10. Congenital Muscular Dystrophy with Cardiac Involvement", "short": "The most common congenital muscular dystrophies are Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy. They are genetic disorders that cause progressive muscle weakness and wasting."}, {"id": "63eeed0af36125a426000007", "type": "factoid", "body": "What disease can be treated with Teclistamab?", "ideal": "Teclistamab is a monoclonal antibody used to treat a rare type of lymphoma called relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is a type of immunotherapy that works by targeting a protein called CD19, which is found on the surface of B-cells. Teclistamab is used in combination with chemotherapy to treat DLBCL that has not responded to other treatments. It has been shown to be effective in improving overall survival and progression-free survival in patients with relapsed or refractory DLBCL.", "exacta":"", "Answer": ["Non-Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia", "Diffuse Large B-Cell Lymphoma", "Mantle Cell Lymphoma"], "clave": "1. Teclistamab\n2. Multiple Myeloma\n3. Immunomodulatory Drug\n4. Monoclonal Antibody\n5. B-Cell Maturation Antigen\n6. CD38 Antigen\n7. Proteasome Inhibitor\n8. Carfilzomib\n9. Lenalidomide\n10. Dexamethasone", "short": "Teclistamab is a monoclonal antibody used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It works by targeting and blocking a protein called CD19, which is found"}, {"id": "643d3e6157b1c7a315000034", "type": "list", "body": "Please list the natriuretic peptides.", "ideal": "Natriuretic peptides are a group of hormones that are released from the heart and other organs in response to increased blood pressure. They are responsible for regulating blood pressure, fluid balance, and electrolyte balance in the body. The three main types of natriuretic peptides are atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). ANP is released from the atria of the heart and helps to reduce blood pressure by increasing the excretion of sodium and water from the kidneys. BNP is released from the ventricles of the heart and helps to reduce blood pressure by decreasing the amount of sodium and water reabsorbed by the kidneys. CNP is released from the vascular endothelium and helps to regulate blood pressure by increasing the production of nitric oxide.", "exacta": ["Atrial Natriuretic Peptide (ANP)", "Brain Natriuretic Peptide (BNP)", "C-Type Natriuretic Peptide (CNP)"], "clave": "Answer: Natriuretic peptides, ANP, BNP, CNP, urodilatin, atrial natriuretic peptide, brain natriuretic peptide, C-type natriuretic peptide, natriuretic peptide receptor, guanylyl cyclase, natriuretic peptide clearance receptor.", "short": "The natriuretic peptides are hormones that regulate blood pressure and fluid balance. They include atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natri"}, {"id": "63f9ee5c33942b094c000014", "type": "yesno", "body": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?", "ideal": "SRRM4 is a splicing regulator that has been found to be involved in the neuronal-specific microexon splicing of TAF1 mRNA. Studies have shown that SRRM4 binds to the microexon of TAF1 mRNA and is necessary for its splicing. Additionally, SRRM4 has been found to be essential for the proper expression of TAF1 in neurons.", "exacta": "No", "clave": ".\n\n1. SRRM4 \n2. Neuronal-specific \n3. Microexon \n4. Splicing \n5. TAF1 \n6. mRNA \n7. Alternative Splicing \n8. Pre-mRNA \n9. Intron \n10. Exon", "short": "Yes, SRRM4 has been shown to regulate neuronal-specific microexon splicing of TAF1 mRNA. It is involved in the recognition of the microexon and the recruitment of the splicing machinery."}, {"id": "644281e557b1c7a31500005b", "type": "summary", "body": "What is the difference between Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1) and type 2 (FSHD2)?", "ideal": "Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder that affects the muscles of the face, shoulders, and upper arms. FSHD1 is caused by a genetic mutation that results in the deletion of a section of DNA on chromosome 4. FSHD2 is caused by a mutation in the DUX4 gene, which is located on chromosome 10. FSHD1 is the most common form of FSHD, while FSHD2 is much rarer. Both types of FSHD cause progressive muscle weakness and wasting, but FSHD2 is typically more severe and can affect other parts of the body.", "exacta": "", "clave": "FSHD1:\n\n-D4Z4 Repeat Expansion\n-Myotonic Dystrophy Protein Kinase (DMPK)\n-Chromosome 4q35\n-Reduced Facioscapulohumeral Muscular Dystrophy (R-FSHD)\n\nFSHD2:\n\n-SMCHD1 Gene\n-Chromosome 18q12\n-Epigenetic Silencing\n-Non-Reduced Facioscapulohumeral Muscular Dystrophy (NR-FSHD)", "short": "FSHD1 is caused by a genetic mutation on chromosome 4, while FSHD2 is caused by a genetic mutation on chromosome 10. FSHD1 is more common and typically presents with more severe symptoms than FSHD2"}, {"id": "63f03ea0f36125a426000020", "type": "factoid", "body": "SER-109 is developed for prevention of which disease?", "ideal": "SER-109 is a novel therapeutic developed by Seres Therapeutics for the prevention of recurrent Clostridioides difficile infection (CDI). It is a microbiome therapeutic consisting of a combination of live bacterial spores that are designed to restore a healthy balance of bacteria in the gut. SER-109 has been studied in clinical trials and has been shown to reduce the risk of recurrent CDI by up to 90%.", "exacta": "Answer: [1] Malaria, [2] Dengue, [3] Zika, [4] Chikungunya, [5] Yellow Fever", "clave": "1. Coronavirus\n2. SARS-CoV-2\n3. Respiratory Infection\n4. Viral Pathogen\n5. Vaccine\n6. Immunization\n7. Prophylaxis\n8. Antibody\n9. Antigen\n10. Serological Test", "short": "SER-109 is a therapeutic vaccine developed to prevent Clostridioides difficile infection, a type of bacterial infection that can cause severe diarrhea and other symptoms."}, {"id": "6431f71057b1c7a315000019", "type": "yesno", "body": "In twin-twin transfusion syndrome, are the twins identical?", "ideal": "Twin-twin transfusion syndrome (TTTS) is a rare condition that affects identical twins who share a placenta. It occurs when the blood vessels in the placenta become connected, allowing blood to flow from one twin (the donor) to the other (the recipient). As a result, the donor twin has too little blood and the recipient twin has too much. The twins are always identical, as they come from the same fertilized egg.", "exacta": "Yes", "clave": "1. Monochorionic-diamniotic (Mo-Di)\n2. Monozygotic (MZ)\n3. Dichorionic-diamniotic (Di-Di)\n4. Polyzygotic (PZ)\n5. Fetal-Fetal Transfusion Syndrome (FFTS)\n6. Inter-Twin Transfusion (ITT)\n7. Umbilical Cord Anastomosis (UCA)\n8. Twin-Twin Transfusion Syndrome (TTTS)", "short": "Yes, the twins in twin-twin transfusion syndrome are identical. They share the same placenta and have the same genetic makeup."}, {"id": "6414c1ae690f196b51000003", "type": "summary", "body": "What is the definition of trichotillomania?", "ideal": "Trichotillomania is a mental disorder characterized by the recurrent urge to pull out one's own hair, resulting in noticeable hair loss. It is classified as an impulse control disorder, and is often associated with feelings of tension or stress prior to pulling, as well as relief or pleasure afterwards. It can affect any area of the body where hair grows, and can have a significant impact on a person's quality of life.", "exacta": "", "clave": "1. Excoriation \n2. Impulse Control Disorder \n3. Compulsive Hair Pulling \n4. Psychogenic Alopecia \n5. Recurrent Hair Pulling \n6. Body-Focused Repetitive Behavior \n7. Self-Inflicted Hair Loss \n8. Pathological Grooming \n9. Trichophagia \n10. Trichotemnomania", "short": "Trichotillomania is a mental disorder characterized by the recurrent urge to pull out one's own hair, resulting in noticeable hair loss."}, {"id": "64179113690f196b5100002e", "type": "factoid", "body": "Where is the DMD gene located?", "ideal": "The DMD gene is located on the X chromosome and is responsible for encoding the dystrophin protein. Dystrophin is a protein found in muscle cells that helps keep them stable and functioning properly. Mutations in the DMD gene can lead to Duchenne muscular dystrophy, a severe form of muscular dystrophy.", "exacta": "1. Chromosome X \n2. Xq21.2-q21.31 \n3. X-linked \n4. Duchenne Muscular Dystrophy \n5. Dystrophin", "clave": "Answer: Chromosome X, Xp21.2, Dystrophin, X-linked recessive, Muscular Dystrophy.", "short": "The DMD gene is located on the X chromosome. It is a large gene that encodes for the dystrophin protein, which is essential for muscle function."}, {"id": "64040c6b201352f04a00000f", "type": "summary", "body": "What is the mechanism of action of Tolebrutinib?", "ideal": "Tolebrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking the activity of BTK, an enzyme involved in the B-cell receptor signaling pathway. This pathway is important for B-cell survival and proliferation, and by blocking BTK, Tolebrutinib can reduce the number of B-cells and prevent them from growing and dividing. This mechanism of action makes Tolebrutinib an effective treatment for certain types of B-cell malignancies.", "exacta": "", "clave": "Tolebrutinib: Tyrosine Kinase Inhibitor, Bruton's Tyrosine Kinase (BTK), B-cell Receptor Signaling Pathway, Phosphorylation, Janus Kinase (JAK), Non-Receptor Tyrosine Kinase, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-6 (IL-6), Interleukin-13 (IL-13), Interleukin-21 (IL-21), Interleukin-31 (IL-31), Interleukin-33 (IL-33), Interleukin-37 (IL-37), Interleukin-38 (IL-38), Interleukin-39 (IL-39), Interleukin-41 (IL-41), Interleukin-42 (IL-42), Interleukin-", "short": "Tolebrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that works by blocking the activity of BTK, which is involved in the signaling pathways that lead to inflammation and autoimmune diseases."}, {"id": "6415b7b8690f196b5100000c", "type": "yesno", "body": "Optogenetics refers to the study of gene expression optimization", "ideal": "using light.\n\nOptogenetics is a field of study that uses light to control and manipulate gene expression. It is a powerful tool for studying the function of genes and their role in biological processes. It involves the use of light-sensitive proteins, such as opsins, to control the activity of specific genes. This technology has been used to study a wide range of biological processes, including cell signaling, neuronal activity, and gene regulation. It has also been used to develop treatments for a variety of diseases, including Parkinson's and Alzheimer's.", "exacta": "Yes", "clave": "1. Light-activated proteins\n2. Photoreceptors\n3. Neurotransmitter release\n4. Optogenetic manipulation\n5. Optogenetic stimulation\n6. Optogenetic inhibition\n7. Optogenetic control\n8. Optogenetic engineering\n9. Optogenetic silencing\n10. Optogenetic tagging", "short": "Optogenetics is a field of study that uses light to control and study gene expression in cells, allowing researchers to better understand how genes work and how they can be manipulated."}, {"id": "6415c9e9690f196b51000018", "type": "factoid", "body": "Which form of breast cancer has Keytruda been FDA approved for?", "ideal": "Keytruda (pembrolizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic triple-negative breast cancer (mTNBC). It is the first immunotherapy approved for this form of breast cancer, which is an aggressive and difficult-to-treat type of cancer. Keytruda is approved for use in combination with chemotherapy for the treatment of adult and pediatric patients with mTNBC.", "exacta": "Answer: \n1. Triple-Negative Breast Cancer \n2. Metastatic Breast Cancer \n3. HER2-Positive Breast Cancer \n4. Advanced Breast Cancer \n5. Early-Stage Breast Cancer", "clave": ".\n\n-Triple-negative breast cancer\n-Metastatic breast cancer\n-PD-L1 expression\n-Monoclonal antibody\n-Immunotherapy\n-Pembrolizumab (Keytruda)\n-Programmed cell death protein 1 (PD-1)", "short": "Keytruda has been FDA approved for metastatic triple-negative breast cancer, a form of breast cancer that does not respond to hormone therapy."}, {"id": "64178f94690f196b51000027", "type": "summary", "body": "What is eteplirsen's mechanism of action?", "ideal": "Eteplirsen is an antisense oligonucleotide drug developed by Sarepta Therapeutics. It works by targeting a specific mutation in the dystrophin gene, which is responsible for Duchenne muscular dystrophy (DMD). The drug binds to the mutated dystrophin gene and helps to restore the production of a functional dystrophin protein. This helps to improve muscle function and reduce the progression of DMD symptoms.", "exacta": "", "clave": "Eteplirsen: Exon Skipping, Antisense Oligonucleotide, Morpholino, Dystrophin, Exon 51, Duchenne Muscular Dystrophy, Splicing, RNA Interference, Post-Transcriptional Modification.", "short": "Eteplirsen works by skipping over a mutated exon in the dystrophin gene, allowing the body to produce a shorter but functional form of the protein."}, {"id": "63f03155f36125a426000019", "type": "yesno", "body": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?", "ideal": "DNX-2401 is an experimental drug developed by DNAtrix, Inc. for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG). The drug has been tested in a Phase 1 clinical trial, which showed that it was safe and well-tolerated in pediatric patients with DIPG. The results of the trial also showed that the drug had some anti-tumor activity in some patients. Further clinical trials are needed to determine the efficacy of DNX-2401 in treating DIPG.", "exacta": "No", "clave": "1. Diffuse Intrinsic Pontine Glioma (DIPG)\n2. DNX-2401\n3. Oncology\n4. Neuro-oncology\n5. Glioma\n6. Clinical Trial\n7. Drug Therapy\n8. Chemotherapy\n9. Radiotherapy\n10. Targeted Therapy", "short": "No, DNX-2401 has not been tested for treatment of Diffuse Intrinsic Pontine Glioma. DNX-2401 is an experimental gene therapy being studied for the treatment of glioblastoma."}]}